Current Report Filing (8-k)

false0001419600MAMANASDAQus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberInitially, the maximum number of shares of the Company's common stock that may be issued pursuant to stock awards under the 2013 Plan was 2,337,616, which is the sum of (i) 1,230,012 shares, plus (ii) the number of shares remaining available for grant under the 2009 Plan, plus (iii) any shares subject to outstanding stock options or other stock awards that would have otherwise returned to the 2009 Plan (such as upon the expiration or termination of a stock award prior to vesting).P2Y 0001419600 2020-05-20 2020-05-20 0001419600 2020-03-30 2020-03-30 0001419600 2019-01-01 2019-03-31 0001419600 2019-04-01 2019-06-30 0001419600 2019-07-01 2019-09-30 0001419600 2019-10-01 2019-12-31 0001419600 2018-01-01 2018-03-31 0001419600 2018-04-01 2018-06-30 0001419600 2018-07-01 2018-09-30 0001419600 2018-10-01 2018-12-31 0001419600 2019-01-01 2019-12-31 0001419600 2018-01-01 2018-12-31 0001419600 2017-01-01 2017-12-31 0001419600 2019-12-31 0001419600 2018-12-31 0001419600 2017-12-31 0001419600 2013-05-31 0001419600 2013-05-01 2013-05-31 0001419600 2019-01-01 0001419600 2016-12-31 0001419600 flxn:Covid19Member 2019-01-01 2019-12-31 0001419600 flxn:TwoThousandTwentyFourConvertibleNotesMember 2019-01-01 2019-12-31 0001419600 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001419600 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0001419600 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-12-31 0001419600 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001419600 us-gaap:OperatingExpenseMember 2019-01-01 2019-12-31 0001419600 us-gaap:InventoriesMember 2019-01-01 2019-12-31 0001419600 flxn:DecreaseRecordedAsBenefitToIncomeTaxProvisionMember 2019-01-01 2019-12-31 0001419600 flxn:DecreasesRecordedAsBenefitToEquityMember 2019-01-01 2019-12-31 0001419600 flxn:IncreasesRecordedToIncomeTaxProvisionMember 2019-01-01 2019-12-31 0001419600 flxn:UnitedKingdomFacilityAtPatheonUKLimitedMember us-gaap:ProductMember 2019-01-01 2019-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001419600 flxn:ComputersOfficeEquipmentAndMinorComputerSoftwareMember 2019-01-01 2019-12-31 0001419600 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-01 2019-12-31 0001419600 us-gaap:EquipmentMember srt:MinimumMember 2019-01-01 2019-12-31 0001419600 us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001419600 us-gaap:EquipmentMember srt:MaximumMember 2019-01-01 2019-12-31 0001419600 flxn:ServiceFeesAllowancesAndChargebacksMember 2019-01-01 2019-12-31 0001419600 flxn:GovernmentRebatesAndOtherIncentivesMember 2019-01-01 2019-12-31 0001419600 flxn:ProductReturnsMember 2019-01-01 2019-12-31 0001419600 flxn:PurchaserProviderDiscountsAndRebatesMember 2019-01-01 2019-12-31 0001419600 flxn:ProductRevenueAllowanceAndReserveMember 2019-01-01 2019-12-31 0001419600 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001419600 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001419600 us-gaap:DomesticCountryMember 2019-01-01 2019-12-31 0001419600 us-gaap:StateAndLocalJurisdictionMember 2019-01-01 2019-12-31 0001419600 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2019-01-01 2019-12-31 0001419600 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-01-01 2019-12-31 0001419600 flxn:TwoThousandThirteenEquityIncentivePlanMember 2019-01-01 2019-12-31 0001419600 flxn:EmployeesStockPurchasePlanMember 2019-01-01 2019-12-31 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember 2019-01-01 2019-12-31 0001419600 flxn:SiliconValleyBankMember flxn:TwoThousandNineteenTermLoanMember 2019-01-01 2019-12-31 0001419600 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001419600 us-gaap:EmployeeStockOptionMember flxn:NonEmployeeDirectorsMember 2019-01-01 2019-12-31 0001419600 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001419600 us-gaap:EmployeeStockOptionMember flxn:NonEmployeeDirectorsMember flxn:ShareBasedCompensationAwardVestingTermTwoMember 2019-01-01 2019-12-31 0001419600 flxn:ShareBasedCompensationAwardVestingTermOneMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001419600 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001419600 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2019-01-01 2019-12-31 0001419600 srt:MaximumMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember flxn:CustomerOneMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember flxn:CustomerTwoMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember flxn:CustomerThreeMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember flxn:CustomerFourMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flxn:CustomerOneMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flxn:CustomerTwoMember 2019-01-01 2019-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flxn:CustomerThreeMember 2019-01-01 2019-12-31 0001419600 flxn:JanuaryZeroFourTwoThousandSixteenMember us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-01 2019-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember flxn:ShareBasedCompensationAwardTrancheFourMember 2019-01-01 2019-12-31 0001419600 stpr:MA 2019-01-01 2019-12-31 0001419600 flxn:MidCapFinancialTrustMember flxn:TwoThousandFifteenTermLoanMember 2019-01-01 2019-12-31 0001419600 flxn:TwoThousandFifteenTermLoanMember 2019-01-01 2019-12-31 0001419600 flxn:WoburnMassachusettsMember 2019-01-01 2019-12-31 0001419600 flxn:ManufacturingAndSupplyAgreementWithPatheonUKLimitedMember 2019-01-01 2019-12-31 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2019-01-01 2019-12-31 0001419600 flxn:EvonikCorporationMember 2019-01-01 2019-12-31 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2019-01-01 2019-12-31 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-01-01 2019-12-31 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember flxn:DebtInstrumentRedemptionPeriodThreeYearsAndThereafterMember 2019-01-01 2019-12-31 0001419600 flxn:XenonPharmaceuticalsIncXenonMember flxn:DefinitiveAgreementMember 2019-01-01 2019-12-31 0001419600 flxn:TwoThousandTwentyFourConvertibleNotesMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-01-01 2019-12-31 0001419600 flxn:TwoThousandTwentyFourConvertibleNotesMember srt:MaximumMember 2019-01-01 2019-12-31 0001419600 flxn:TwoThousandTwentyFourConvertibleNotesMember 2019-12-31 0001419600 flxn:TwoThousandFifteenTermLoanMember 2019-12-31 0001419600 flxn:ComputerAndOfficeEquipmentMember 2019-12-31 0001419600 us-gaap:EquipmentMember 2019-12-31 0001419600 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001419600 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-12-31 0001419600 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001419600 us-gaap:ConstructionInProgressMember 2019-12-31 0001419600 flxn:USGovernmentObligationsMember 2019-12-31 0001419600 us-gaap:CorporateBondSecuritiesMember 2019-12-31 0001419600 us-gaap:CommercialPaperMember 2019-12-31 0001419600 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001419600 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001419600 us-gaap:DomesticCountryMember 2019-12-31 0001419600 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001419600 us-gaap:ResearchMember us-gaap:DomesticCountryMember 2019-12-31 0001419600 us-gaap:ResearchMember us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001419600 flxn:TwoThousandThirteenEquityIncentivePlanMember srt:MaximumMember 2019-12-31 0001419600 flxn:TwoThousandThirteenEquityIncentivePlanMember 2019-12-31 0001419600 flxn:EmployeesStockPurchasePlanMember 2019-12-31 0001419600 flxn:TwoThousandThirteenEquityIncentivePlanMember flxn:InducementAwardsMember 2019-12-31 0001419600 flxn:TwoThousandAndNineStockIncentivePlanMember 2019-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember flxn:JanuaryZeroFourTwoThousandSixteenMember 2019-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001419600 stpr:MA 2019-12-31 0001419600 flxn:TwoThousandTwentyFourConvertibleNotesMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-12-31 0001419600 flxn:SiliconValleyBankMember flxn:TwoThousandFifteenTermLoanMember 2019-12-31 0001419600 flxn:WoburnMassachusettsMember 2019-12-31 0001419600 flxn:ManufacturingAndSupplyAgreementWithPatheonUKLimitedMember 2019-12-31 0001419600 us-gaap:DebtInstrumentRedemptionPeriodOneMember 2019-12-31 0001419600 us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-12-31 0001419600 us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2019-12-31 0001419600 flxn:DebtInstrumentRedemptionPeriodFourYearsAndThereafterMember 2019-12-31 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember 2019-12-31 0001419600 flxn:ManufacturingAndSupplyAgreementWithPatheonUKLimitedMember 2018-12-31 0001419600 flxn:ComputerAndOfficeEquipmentMember 2018-12-31 0001419600 us-gaap:EquipmentMember 2018-12-31 0001419600 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001419600 us-gaap:ComputerSoftwareIntangibleAssetMember 2018-12-31 0001419600 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001419600 us-gaap:ConstructionInProgressMember 2018-12-31 0001419600 us-gaap:CommercialPaperMember 2018-12-31 0001419600 flxn:USGovernmentObligationsMember 2018-12-31 0001419600 us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001419600 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001419600 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001419600 flxn:WoburnMassachusettsMember 2018-12-31 0001419600 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001419600 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001419600 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-12-31 0001419600 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001419600 flxn:DecreaseRecordedAsBenefitToIncomeTaxProvisionMember 2018-01-01 2018-12-31 0001419600 flxn:DecreasesRecordedAsBenefitToEquityMember 2018-01-01 2018-12-31 0001419600 flxn:IncreasesRecordedToIncomeTaxProvisionMember 2018-01-01 2018-12-31 0001419600 flxn:ServiceFeesAllowancesAndChargebacksMember 2018-01-01 2018-12-31 0001419600 flxn:GovernmentRebatesAndOtherIncentivesMember 2018-01-01 2018-12-31 0001419600 flxn:ProductReturnsMember 2018-01-01 2018-12-31 0001419600 flxn:ProductRevenueAllowanceAndReserveMember 2018-01-01 2018-12-31 0001419600 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001419600 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001419600 flxn:EmployeesStockPurchasePlanMember 2018-01-01 2018-12-31 0001419600 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001419600 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001419600 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2018-01-01 2018-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember flxn:CustomerOneMember 2018-01-01 2018-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember flxn:CustomerTwoMember 2018-01-01 2018-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flxn:CustomerOneMember 2018-01-01 2018-12-31 0001419600 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flxn:CustomerTwoMember 2018-01-01 2018-12-31 0001419600 flxn:GeneQuineBiotherapeuticsGmbHMember flxn:DefinitiveAgreementMember 2018-01-01 2018-12-31 0001419600 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001419600 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0001419600 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-12-31 0001419600 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001419600 flxn:DecreaseRecordedAsBenefitToIncomeTaxProvisionMember 2017-01-01 2017-12-31 0001419600 flxn:DecreasesRecordedAsBenefitToEquityMember 2017-01-01 2017-12-31 0001419600 flxn:IncreasesRecordedToIncomeTaxProvisionMember 2017-01-01 2017-12-31 0001419600 flxn:ServiceFeesAllowancesAndChargebacksMember 2017-01-01 2017-12-31 0001419600 flxn:GovernmentRebatesAndOtherIncentivesMember 2017-01-01 2017-12-31 0001419600 flxn:ProductReturnsMember 2017-01-01 2017-12-31 0001419600 flxn:ProductRevenueAllowanceAndReserveMember 2017-01-01 2017-12-31 0001419600 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001419600 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001419600 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001419600 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001419600 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001419600 flxn:SiliconValleyBankMember flxn:TwoThousandTwentyAmendedTermLoanMember 2019-08-02 0001419600 flxn:TwoThousandNineteenTermLoanMember flxn:SiliconValleyBankMember 2019-08-02 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember 2019-08-02 0001419600 flxn:SiliconValleyBankMember flxn:TwoThousandFifteenTermLoanMember 2019-08-02 0001419600 flxn:SiliconValleyBankAndMidCapFinancialFundingXIIITrustMember flxn:TwoThousandNineteenTermLoanMember 2019-08-02 2019-08-02 0001419600 flxn:SiliconValleyBankAndMidCapFinancialFundingXIIITrustMember flxn:TwoThousandFifteenTermLoanMember 2019-08-02 2019-08-02 0001419600 flxn:SiliconValleyBankMember flxn:TwoThousandNineteenTermLoanMember us-gaap:InterestOnlyStripMember 2019-08-02 2019-08-02 0001419600 flxn:SiliconValleyBankMember flxn:TwoThousandNineteenTermLoanMember us-gaap:PrincipalOnlyStripMember 2019-08-02 2019-08-02 0001419600 flxn:FollowOnPublicOfferingMember 2017-10-15 2017-10-16 0001419600 flxn:FollowOnPublicOfferingMember 2017-10-16 0001419600 flxn:TwoThousandTwentyFourConvertibleNotesMember 2017-05-02 0001419600 flxn:TwoThousandTwentyFourConvertibleNotesMember 2017-05-01 2017-05-02 0001419600 flxn:MidCapFinancialTrustMember flxn:TwoThousandFifteenTermLoanMember 2015-08-04 0001419600 flxn:MidCapFinancialTrustMember flxn:TwoThousandFifteenTermLoanMember 2019-08-01 2019-08-31 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember 2020-02-01 2020-02-29 0001419600 flxn:TwoThousandTwentyFourConvertibleNotesMember 2019-01-01 2019-06-30 0001419600 flxn:FollowOnPublicOfferingMember 2016-06-06 2016-06-07 0001419600 flxn:FollowOnPublicOfferingMember 2016-06-07 0001419600 flxn:FollowOnPublicOfferingMember 2016-11-14 2016-11-15 0001419600 flxn:FollowOnPublicOfferingMember 2016-11-15 0001419600 flxn:TwoThousandThirteenEquityIncentivePlanMember 2017-09-10 2017-09-11 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2016-01-04 2016-01-04 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2017-10-05 2017-10-06 0001419600 stpr:MA 2017-10-05 2017-10-06 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2017-10-01 2017-12-31 0001419600 stpr:MA 2015-07-31 0001419600 stpr:MA 2015-09-30 0001419600 stpr:MA 2016-09-21 0001419600 stpr:MA 2015-07-01 2015-07-31 0001419600 flxn:ManufacturingAndSupplyAgreementWithPatheonUKLimitedMember 2015-07-01 2015-07-31 0001419600 stpr:MA 2016-09-20 2016-09-21 0001419600 stpr:MA 2017-04-06 2017-04-07 0001419600 stpr:MA 2017-04-07 0001419600 stpr:MA 2016-11-01 2017-10-31 0001419600 stpr:MA 2017-10-06 0001419600 stpr:MA 2019-06-30 0001419600 flxn:ManufacturingAndSupplyAgreementWithPatheonUKLimitedMember 2019-06-30 0001419600 flxn:WoburnMassachusettsMember 2017-02-28 0001419600 flxn:WoburnMassachusettsMember 2017-02-01 2017-02-28 0001419600 flxn:ManufacturingAndSupplyAgreementWithPatheonUKLimitedMember 2019-06-01 2019-06-30 0001419600 flxn:EvonikCorporationMember 2016-11-01 2016-11-30 0001419600 flxn:ZilrettaMember flxn:SouthWestResearchInstituteMember us-gaap:LicenseAgreementTermsMember 2014-07-24 2014-07-25 0001419600 flxn:DefinitiveAgreementMember flxn:GeneQuineBiotherapeuticsGmbHMember 2017-12-01 2017-12-31 0001419600 flxn:Phase2ProofOfConceptClinicalTrialMember srt:MaximumMember flxn:DefinitiveAgreementMember flxn:GeneQuineBiotherapeuticsGmbHMember 2017-12-01 2017-12-31 0001419600 srt:MaximumMember flxn:DefinitiveAgreementMember flxn:GeneQuineBiotherapeuticsGmbHMember 2017-12-01 2017-12-31 0001419600 flxn:DefinitiveAgreementMember flxn:GeneQuineBiotherapeuticsGmbHMember flxn:InvestigationalNewDrugMember 2019-11-01 2019-11-30 0001419600 flxn:PhaseOneClinicalTrialMember 2020-03-01 2020-03-31 0001419600 flxn:DefinitiveAgreementMember flxn:XenonPharmaceuticalsIncXenonMember 2019-09-01 2019-09-30 0001419600 flxn:Phase2ProofOfConceptClinicalTrialMember flxn:XenonPharmaceuticalsIncXenonMember flxn:DefinitiveAgreementMember srt:MaximumMember 2019-09-01 2019-09-30 0001419600 srt:MaximumMember flxn:DefinitiveAgreementMember flxn:XenonPharmaceuticalsIncXenonMember 2019-09-01 2019-09-30 0001419600 flxn:SalesRelatedMilestonePaymentsMember flxn:XenonPharmaceuticalsIncXenonMember flxn:DefinitiveAgreementMember 2019-09-01 2019-09-30 0001419600 us-gaap:CollaborativeArrangementMember flxn:HkTainuoMember 2020-03-30 2020-03-30 0001419600 flxn:SiliconValleyBankMember flxn:TwoThousandTwentyAmendedTermLoanMember 2020-05-18 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember 2020-02-29 2020-02-29 0001419600 flxn:SiliconValleyBankMember us-gaap:RevolvingCreditFacilityMember 2020-05-18 2020-05-18 0001419600 flxn:SiliconValleyBankMember flxn:TwoThousandTwentyAmendedTermLoanMember 2020-05-18 2020-05-18 0001419600 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001419600 flxn:ServiceFeesAllowancesAndChargebacksMember 2019-12-31 0001419600 flxn:GovernmentRebatesAndOtherIncentivesMember 2019-12-31 0001419600 flxn:ProductReturnsMember 2019-12-31 0001419600 flxn:PurchaserProviderDiscountsAndRebatesMember 2019-12-31 0001419600 flxn:ProductRevenueAllowanceAndReserveMember 2019-12-31 0001419600 us-gaap:CommonStockMember 2019-12-31 0001419600 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001419600 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001419600 us-gaap:RetainedEarningsMember 2019-12-31 0001419600 flxn:ServiceFeesAllowancesAndChargebacksMember 2018-12-31 0001419600 flxn:GovernmentRebatesAndOtherIncentivesMember 2018-12-31 0001419600 flxn:ProductReturnsMember 2018-12-31 0001419600 flxn:ProductRevenueAllowanceAndReserveMember 2018-12-31 0001419600 us-gaap:CommonStockMember 2018-12-31 0001419600 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001419600 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001419600 us-gaap:RetainedEarningsMember 2018-12-31 0001419600 us-gaap:CommonStockMember 2016-12-31 0001419600 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001419600 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001419600 us-gaap:RetainedEarningsMember 2016-12-31 0001419600 flxn:ServiceFeesAllowancesAndChargebacksMember 2016-12-31 0001419600 flxn:GovernmentRebatesAndOtherIncentivesMember 2016-12-31 0001419600 flxn:ProductReturnsMember 2016-12-31 0001419600 flxn:PurchaserProviderDiscountsAndRebatesMember 2016-12-31 0001419600 flxn:ProductRevenueAllowanceAndReserveMember 2016-12-31 0001419600 flxn:ServiceFeesAllowancesAndChargebacksMember 2017-12-31 0001419600 flxn:GovernmentRebatesAndOtherIncentivesMember 2017-12-31 0001419600 flxn:ProductReturnsMember 2017-12-31 0001419600 flxn:ProductRevenueAllowanceAndReserveMember 2017-12-31 0001419600 us-gaap:CommonStockMember 2017-12-31 0001419600 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001419600 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001419600 us-gaap:RetainedEarningsMember 2017-12-31 iso4217:USD xbrli:pure xbrli:shares utr:sqft iso4217:USD xbrli:shares flxn:Customer flxn:Installment flxn:Term utr:D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2020

Flexion Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-36287	26-1388364
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)


10 Mall Road, Suite 301, Burlington, Massachusetts		01803
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 305-7777

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $0.001	FLXN	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 8.01

Other Events.

In connection with the issuance of the report of its independent registered public accounting firm as part of its recently announced proposed public offering of common stock, Flexion Therapeutics, Inc. (the “Company”) is refiling as Exhibit 99.1 hereto its consolidated financial statements that were previously included in its Annual Report on Form 10-K for the year ended December 31, 2019 (the “Form 10-K”) and the related report of the Company’s independent registered public accounting firm. The financial statements filed as Exhibit 99.1 hereto are identical to those included in the Form 10-K other than (i) an update to Note 1 to the consolidated financial statements to disclose, (a) consistent with the disclosures appearing in the Company’s previously filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and due to circumstances arising after the filing of the Form 10-K on March 12, 2020, that there was substantial doubt about its ability to continue as a going concern, and (b) the Company entered into an amendment to its credit and security agreement with Silicon Valley Bank as agent, MidCap Financial Trust, Flexpoint MCLS Holdings, LLC, and the other lenders from time to time party thereto and (ii) to add Note 18 to the consolidated financial statements describing subsequent events that occurred after the Form 10-K was filed on March 12, 2020. The report of the Company’s independent registered public accounting firm included in Exhibit 99.1 hereto likewise includes a paragraph noting management’s conclusion regarding substantial doubt about the Company’s ability to continue as a going concern. Other than as described in the preceding sentences, Exhibit 99.1 does not revise, modify, update or otherwise affect the Form 10-K, including the consolidated financial statements.

This Form 8-K is being filed only for the purposes described above, and all other information in the Form 10-K remains unchanged. In order to preserve the nature and character of the disclosures set forth in the Form 10-K, the items included in Exhibit 99.1 of this Form 8-K have been updated solely for the matters described above. No attempt has been made in this Form 8-K to reflect events or occurrences after the date of the filing of the Form 10-K on March 12, 2020, and it should not be read to modify or update other disclosures as presented in the Form 10-K. As a result, this Form 8-K should be read in conjunction with the Form 10-K and the Company’s filings made with the SEC subsequent to the filing of the Form 10-K. References in the attached exhibits to the Form 10-K or parts thereof refer to the Form 10-K for the year ended December 31, 2019, filed on March 12, 2020.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.


Exhibit Number		Description

	23.1	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm

	99.1	Financial Statements and Supplementary Data

	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.